Miguel Leon-Sanz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Miguel Leon-Sanz has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Anders Thorell
Department of Surgery & Anaesthesiology, Ersta Hospital, Stockholm, Sweden
4 shared publications - Arved Weimann
Department of General, Visceral and Oncological Surgery Clinical Nutrition Unit, Hospital St. George Leipzig Germany
4 shared publications - Cristina Cuerda
Nutrition Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain
4 shared publications - Rocco Barazzoni
Department of Medical, Technological and Translational Sciences, University of Trieste, Ospedale di Cattinara, Trieste, Italy
4 shared publications - Stephan C. Bischoff
Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany
4 shared publications - Ahad Eshraghian
Shiraz Transplant Center, Abu-Ali Sina Hospital, Shiraz, Iran
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Elsevier in Primary Care Diabetes
- Vol. 20 (5) , 620-628
A cross-regional initiative for improving type 2 diabetes mellitus care quality measurement in Spain – The Diabetes Lighthouse project
- 10 August 2026
- Published by Elsevier in Primary Care Diabetes
- Vol. 20 (5) , 620-628
Open AccessA cross-regional initiative for improving type 2 diabetes mellitus care quality measurement in Spain – The Diabetes Lighthouse project
- 28 May 2026
- Published by Reial Acadèmia de Medicina de les Illes Balears in Academic Journal of Health Sciences
- Vol. 41 (3)
Obesity in occupational health: The position of the occupational physician in preventive practice
Over recent decades, obesity has become firmly established as one of the leading public health problems worldwide, with a steadily increasing prevalence that substantially affects the working-age population. This excess adiposity is associated not only with a higher risk of morbidity and mortality from cardiovascular, metabolic, and musculoskeletal diseases but also with impaired functional capacity among workers, reduced productivity, and diminished long-term participation in the labor market. In the field of occupational health, obesity interacts with organizational, ergonomic, and psychosocial factors, increasing the likelihood of occupational accidents, absenteeism, temporary disability, and early retirement, with a significant impact on both companies and social protection systems. Despite this evidence, obesity remains underrepresented in risk assessment, health surveillance, and preventive policies implemented in workplaces, which continue to focus predominantly on traditional physical, chemical, or biological hazards. This article sets out the positioning of the occupational physician in preventive practice, considering obesity as a key determinant of occupational health. It proposes a comprehensive framework for addressing obesity in the workplace that integrates clinical, preventive, and organizational perspectives, with the aim of informing health policy decisions, guiding corporate strategies, and shaping priority research agendas.
- 28 May 2026
- Published by Reial Acadèmia de Medicina de les Illes Balears in Academic Journal of Health Sciences
- Vol. 41 (3)
Obesity in occupational health: The position of the occupational physician in preventive practice
Over recent decades, obesity has become firmly established as one of the leading public health problems worldwide, with a steadily increasing prevalence that substantially affects the working-age population. This excess adiposity is associated not only with a higher risk of morbidity and mortality from cardiovascular, metabolic, and musculoskeletal diseases but also with impaired functional capacity among workers, reduced productivity, and diminished long-term participation in the labor market. In the field of occupational health, obesity interacts with organizational, ergonomic, and psychosocial factors, increasing the likelihood of occupational accidents, absenteeism, temporary disability, and early retirement, with a significant impact on both companies and social protection systems. Despite this evidence, obesity remains underrepresented in risk assessment, health surveillance, and preventive policies implemented in workplaces, which continue to focus predominantly on traditional physical, chemical, or biological hazards. This article sets out the positioning of the occupational physician in preventive practice, considering obesity as a key determinant of occupational health. It proposes a comprehensive framework for addressing obesity in the workplace that integrates clinical, preventive, and organizational perspectives, with the aim of informing health policy decisions, guiding corporate strategies, and shaping priority research agendas.
- Open Access
- 2 May 2023
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 10, 1182445
Compliance with a high-protein and energy-dense oral nutritional supplement in patients with disease-related malnutrition: a randomized open-label crossover trial
Introduction: Patient compliance with oral nutritional supplements (ONS) is not optimal for meeting energy and nutritional requirements in a high proportion of patients with disease-related malnutrition (DRM). Energy density or prescribed volume of ONS may impact compliance.Methods: A randomized, open-label crossover trial was conducted in outpatients with DRM to compare compliance with a high energy-dense ONS (edONS, 2.4 kcal/mL) and a reference ONS (heONS, 2.0 kcal/mL; NCT05609006). Patients were randomly assigned to two 8-week treatment sequences of four-weeks periods: edONS + heONS (sequence A) or heONS + edONS (sequence B). Patients daily reported the amount of product left over gastrointestinal tolerance and satisfaction with ONS. A non-inferiority analysis was performed to compare the compliance rate (percentage of consumed energy over the prescribed) for each period and sequence.Results: Fifty-three patients were assigned to sequence A and 50 to sequence B (55.7 ± 13.9 years, 37.0% female, 67.1% oncology patients). In sequence A, the compliance rates were 88.6% ± 14.3% vs. 84.1 ± 21.8% (p = 0.183), while in sequence B, they were 78.9% ± 23.8% vs. 84.4% ± 21.4% (p < 0.01). In both sequences, the lower range of the confidence interval for compliance with edONS was greater than the non-inferiority threshold (for sequence A ΔCompA was 4.5% [95% CI, −2.0% to 10.0%], and for sequence, B ΔCompB was 5.6% [95% CI, −3.0% to 14.0%]). The total discarded cost for each ONS was higher for heONS than edONS, being the difference statistically significant in sequence B. BMI increased slightly and not significantly in both sequences, and the percentage of patients with severe malnutrition was reduced. The frequency of gastrointestinal symptoms was low for both sequences, and satisfaction with ONS was slightly higher for edONS.Conclusion: Our findings highlight that edONS was non-inferior to heONS in terms of consumed energy over the prescribed, with a lower amount of edONS discarded, which suggests a higher efficiency of edONS.
- 2 May 2023
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 10, 1182445
Open AccessCompliance with a high-protein and energy-dense oral nutritional supplement in patients with disease-related malnutrition: a randomized open-label crossover trial
Introduction: Patient compliance with oral nutritional supplements (ONS) is not optimal for meeting energy and nutritional requirements in a high proportion of patients with disease-related malnutrition (DRM). Energy density or prescribed volume of ONS may impact compliance.Methods: A randomized, open-label crossover trial was conducted in outpatients with DRM to compare compliance with a high energy-dense ONS (edONS, 2.4 kcal/mL) and a reference ONS (heONS, 2.0 kcal/mL; NCT05609006). Patients were randomly assigned to two 8-week treatment sequences of four-weeks periods: edONS + heONS (sequence A) or heONS + edONS (sequence B). Patients daily reported the amount of product left over gastrointestinal tolerance and satisfaction with ONS. A non-inferiority analysis was performed to compare the compliance rate (percentage of consumed energy over the prescribed) for each period and sequence.Results: Fifty-three patients were assigned to sequence A and 50 to sequence B (55.7 ± 13.9 years, 37.0% female, 67.1% oncology patients). In sequence A, the compliance rates were 88.6% ± 14.3% vs. 84.1 ± 21.8% (p = 0.183), while in sequence B, they were 78.9% ± 23.8% vs. 84.4% ± 21.4% (p < 0.01). In both sequences, the lower range of the confidence interval for compliance with edONS was greater than the non-inferiority threshold (for sequence A ΔCompA was 4.5% [95% CI, −2.0% to 10.0%], and for sequence, B ΔCompB was 5.6% [95% CI, −3.0% to 14.0%]). The total discarded cost for each ONS was higher for heONS than edONS, being the difference statistically significant in sequence B. BMI increased slightly and not significantly in both sequences, and the percentage of patients with severe malnutrition was reduced. The frequency of gastrointestinal symptoms was low for both sequences, and satisfaction with ONS was slightly higher for edONS.Conclusion: Our findings highlight that edONS was non-inferior to heONS in terms of consumed energy over the prescribed, with a lower amount of edONS discarded, which suggests a higher efficiency of edONS.
- 10 April 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (6) , 987-1024
Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
- 10 April 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (6) , 987-1024
Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
- Open Access
- 12 August 2022
- Published by Wiley in United European Gastroenterology Journal
- Vol. 10 (7) , 663-720
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
Background: Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), pancreatitis, and chronic liver disease (CLD) often suffer from obesity because of coincidence (IBD, IBS, celiac disease) or related pathophysiology (GERD, pancreatitis and CLD). It is unclear if such patients need a particular diagnostic and treatment that differs from the needs of lean GI patients. The present guideline addresses this question according to current knowledge and evidence.Objective: The objective of the guideline is to give advice to all professionals working in the field of gastroenterology care including physicians, surgeons, dietitians and others how to handle patients with GI disease and obesity.Methods: The present guideline was developed according to the standard operating procedure for European Society for Clinical Nutrition and Metabolism guidelines, following the Scottish Intercollegiate Guidelines Network grading system (A, B, 0, and good practice point [GPP]). The procedure included an online voting (Delphi) and a final consensus conference.Results: In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity – including sarcopenic obesity – is addressed in a multidisciplinary way. A particular emphasis is on CLD, especially fatty liver disease, since such diseases are closely related to obesity, whereas liver cirrhosis is rather associated with sarcopenic obesity. A special chapter is dedicated to obesity care in patients undergoing bariatric surgery. The guideline focuses on adults, not on children, for whom data are scarce. Whether some of the recommendations apply to children must be left to the judgment of the experienced pediatrician.Conclusion: The present guideline offers for the first time evidence‐based advice how to care for patients with chronic GI diseases and concomitant obesity, an increasingly frequent constellation in clinical practice.
- 12 August 2022
- Published by Wiley in United European Gastroenterology Journal
- Vol. 10 (7) , 663-720
Open AccessEuropean guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
Background: Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), pancreatitis, and chronic liver disease (CLD) often suffer from obesity because of coincidence (IBD, IBS, celiac disease) or related pathophysiology (GERD, pancreatitis and CLD). It is unclear if such patients need a particular diagnostic and treatment that differs from the needs of lean GI patients. The present guideline addresses this question according to current knowledge and evidence.Objective: The objective of the guideline is to give advice to all professionals working in the field of gastroenterology care including physicians, surgeons, dietitians and others how to handle patients with GI disease and obesity.Methods: The present guideline was developed according to the standard operating procedure for European Society for Clinical Nutrition and Metabolism guidelines, following the Scottish Intercollegiate Guidelines Network grading system (A, B, 0, and good practice point [GPP]). The procedure included an online voting (Delphi) and a final consensus conference.Results: In 100 recommendations (3x A, 33x B, 24x 0, 40x GPP, all with a consensus grade of 90% or more) care of GI patients with obesity – including sarcopenic obesity – is addressed in a multidisciplinary way. A particular emphasis is on CLD, especially fatty liver disease, since such diseases are closely related to obesity, whereas liver cirrhosis is rather associated with sarcopenic obesity. A special chapter is dedicated to obesity care in patients undergoing bariatric surgery. The guideline focuses on adults, not on children, for whom data are scarce. Whether some of the recommendations apply to children must be left to the judgment of the experienced pediatrician.Conclusion: The present guideline offers for the first time evidence‐based advice how to care for patients with chronic GI diseases and concomitant obesity, an increasingly frequent constellation in clinical practice.
- Open Access
- 12 August 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (10) , 2364-2405
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
- 12 August 2022
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (10) , 2364-2405
Open AccessEuropean guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
- 7 April 2021
- Published by Wiley in Obesity Reviews
- Vol. 22 (6) , e13253
Response to Letter to the Editor
- 7 April 2021
- Published by Wiley in Obesity Reviews
- Vol. 22 (6) , e13253
Response to Letter to the Editor
- Open Access
- 1 April 2021
- Published by ARAN Ediciones in Nutrición Hospitalaria
- Vol. 38, 29-33
A critical review of the GLIM criteria
Disease-related malnutrition (DRM) is a frequent syndrome in clinical practice, in which the mutual relationship between disease and malnutrition is observed. It is a specific form of malnutrition with causes other than poverty and social problems that make it difficult food production and distribution. Inflammation, anorexia, changes in Cody composition or in energy and protein requirements contribute to the development of DRM. This is associated with an increase in morbidity, mortality and economic expenditure. There are numerous tools to identify patients at risk of malnutrition, but until now there was no general consensus on the diagnostic criteria for malnutrition. The GLIM criteria provide a diagnostic system that has been accepted by the main international scientific societies in the field of clinical nutrition. In this article we describe its development, its application in different populations of patients and its comparison with other criteria or different diagnostic tools that contribute to its validation. This makes it possible to point out the advantages and limitations that have been described so far with the use of the GUM criteria.
- 1 April 2021
- Published by ARAN Ediciones in Nutrición Hospitalaria
- Vol. 38, 29-33
Open AccessA critical review of the GLIM criteria
Disease-related malnutrition (DRM) is a frequent syndrome in clinical practice, in which the mutual relationship between disease and malnutrition is observed. It is a specific form of malnutrition with causes other than poverty and social problems that make it difficult food production and distribution. Inflammation, anorexia, changes in Cody composition or in energy and protein requirements contribute to the development of DRM. This is associated with an increase in morbidity, mortality and economic expenditure. There are numerous tools to identify patients at risk of malnutrition, but until now there was no general consensus on the diagnostic criteria for malnutrition. The GLIM criteria provide a diagnostic system that has been accepted by the main international scientific societies in the field of clinical nutrition. In this article we describe its development, its application in different populations of patients and its comparison with other criteria or different diagnostic tools that contribute to its validation. This makes it possible to point out the advantages and limitations that have been described so far with the use of the GUM criteria.
- Open Access
- 24 August 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (9) , 1301
Nutritional Challenges in Metabolic Syndrome
Metabolic Syndrome (MetS) is a combination of risk factors for the development of cardiovascular disease (CVD) and type 2 diabetes. Different diagnostic criteria were proposed, but a consensus was reached in 2009 based on values of waist circumference, blood pressure, fasting glycemia, triglycerides, and high-density lipoprotein (HDL)-cholesterol levels. The main underlying etiologic factor is insulin resistance. The quality and quantity of individual macronutrients have an influence on the development and resolution of this syndrome. However, the main treatment goal is weight loss and a decrease in insulin resistance. A controlled energy dietary recommendation, together with moderate levels of physical activity, may positively change the parameters of MetS. However, there is no single dietary or exercise prescription that works for all patients. Dietary patterns such as Mediterranean-style, dietary approaches to stop hypertension (DASH), low-carbohydrate, and low-fat diets can ameliorate insulin resistance and MetS. Long-term adherence to a healthy lifestyle is key in assuring that individuals significantly reduce the risk of CVD and diabetes mellitus.
- 24 August 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (9) , 1301
Open AccessNutritional Challenges in Metabolic Syndrome
Metabolic Syndrome (MetS) is a combination of risk factors for the development of cardiovascular disease (CVD) and type 2 diabetes. Different diagnostic criteria were proposed, but a consensus was reached in 2009 based on values of waist circumference, blood pressure, fasting glycemia, triglycerides, and high-density lipoprotein (HDL)-cholesterol levels. The main underlying etiologic factor is insulin resistance. The quality and quantity of individual macronutrients have an influence on the development and resolution of this syndrome. However, the main treatment goal is weight loss and a decrease in insulin resistance. A controlled energy dietary recommendation, together with moderate levels of physical activity, may positively change the parameters of MetS. However, there is no single dietary or exercise prescription that works for all patients. Dietary patterns such as Mediterranean-style, dietary approaches to stop hypertension (DASH), low-carbohydrate, and low-fat diets can ameliorate insulin resistance and MetS. Long-term adherence to a healthy lifestyle is key in assuring that individuals significantly reduce the risk of CVD and diabetes mellitus.
- 1 August 2017
- Published by Elsevier in Clinical Nutrition
- Vol. 36 (4) , 917-938
Towards a multidisciplinary approach to understand and manage obesity and related diseases
- 1 August 2017
- Published by Elsevier in Clinical Nutrition
- Vol. 36 (4) , 917-938
Towards a multidisciplinary approach to understand and manage obesity and related diseases